Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EPS (Basic) (2016 - 2025)

Lexaria Bioscience's EPS (Basic) history spans 10 years, with the latest figure at $0.13 for Q2 2024.

  • For Q2 2024, EPS (Basic) fell 65.13% year-over-year to $0.13; the TTM value through May 2024 reached $0.13, down 65.13%, while the annual FY2023 figure was $1.01, 182.01% up from the prior year.
  • EPS (Basic) for Q2 2024 was $0.13 at Lexaria Bioscience, up from $0.06 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.37 in Q2 2023 and bottomed at -$0.73 in Q3 2022.
  • The 5-year median for EPS (Basic) is -$0.24 (2020), against an average of -$0.13.
  • The largest annual shift saw EPS (Basic) tumbled 4700.0% in 2020 before it soared 193.05% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.24 in 2020, then plummeted by 45.83% to -$0.35 in 2021, then soared by 186.42% to $0.3 in 2022, then crashed by 56.17% to $0.13 in 2023, then fell by 2.01% to $0.13 in 2024.
  • Per Business Quant, the three most recent readings for LEXX's EPS (Basic) are $0.13 (Q2 2024), $0.06 (Q1 2024), and $0.13 (Q4 2023).